An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy.

@article{Striano2007AnOT,
  title={An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy.},
  author={Pasquale Striano and Antonietta Coppola and Marianna Pezzella and Clotilde Ciampa and Nicola Specchio and Francesca Ragona and Maria Margherita Mancardi and Elena Gennaro and Francesca Beccaria and Giuseppe Capovilla and P Rasmini and Dante Besana and G G Coppola and Mirella Elia and Tiziana Granata and Maurizio Vecchi and Federico Vigevano and Maurizio Viri and Roberto Gaggero and Salvatore Striano and Federico Zara},
  journal={Neurology},
  year={2007},
  volume={69 3},
  pages={
          250-4
        }
}
OBJECTIVE To conduct an open-label, add-on trial on safety and efficacy of levetiracetam in severe myoclonic epilepsy of infancy (SMEI). PATIENTS AND METHODS SMEI patients were recruited from different centers according to the following criteria: age > or =3 years; at least four tonic-clonic seizures/month during the last 8 weeks; previous use of at least two drugs. Levetiracetam was orally administrated at starting dose of approximately 10 mg/kg/day up to 50 to 60 mg/kg/day in two doses… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS

Levetiracetam for managing neurologic and psychiatric disorders.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2009
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Recent Advances in the Drug Treatment of Dravet Syndrome

Elaine C. Wirrell, Rima Nabbout
  • CNS Drugs
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Therapie des Dravet-Syndroms

  • Zeitschrift für Epileptologie
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Screening of conventional anticonvulsants in a genetic mouse model of epilepsy

  • Annals of clinical and translational neurology
  • 2017
VIEW 1 EXCERPT
CITES RESULTS